HJC0152 is a signal transducer and activator of transcription 3 (STAT3) inhibitor with remarkably improved aqueous solubility.

HJC 0726 is a potent Exchange proteins directly activated by cAMP (EPAC) inhibitor, inhibits cAMP-mediated EPAC2 GEF activity with IC50 of 1.0 uM.

HIV-1 integrase inhibitor, in the treatment of human immunodeficiency virus (HIV) infection.

HIV-1 Integrase Inhibitor 7 is an allosteric HIV-1 integrase inhibitor that inhibits the LEDGF/p75-integrase interaction with IC50 of 0.58 uM, antiviral activity EC50 of 0.76 uM..

HIV-1 integrase inhibitor ((Z)-4-(3-(azidomethyl)phenyl)-2-hydroxy-4-oxobut-2-enoic acid) is uesful for anti-HIV.

HIV-1 inhibitor 18A is a novel broad HIV-1 inhibitor that blocks envelope glycoprotein transitions critical for entry, specifically inhibits the entry of a wide range of HIV-1 isolates with mean IC50 of 6.4 uM.

Hinokitiol (4-Isopropyltropolone.

HIF2α-IN-2 is a potent, selective, allosteric inhibitor of HIF-2α PAS-B domain with Kd of 81 nM, shows high selectivity and does not affect HIF-1 function.

HG-7-27-01 is a potent, selective c-Fes protein-tyrosine kinase inhibitor with IC50 of 224 nM, displays intermediate selectivity profiles (selectivity score=0.16) against 442 kinases..

HG6-64-1 is a potent dual TAK1 and MAP4K2 ((germinal center kinase, GCK)) inhibitor with IC50 of 41 nM and 98 nM, respectively.

HG-12-6 is a small-molecule inhibitor that bind preferentially to unphosphorylated IRAK4 with IC50 of 165.1 nM, displays 15-fold selectivity over phosphorylated IRAK4 (IC50=2876 nM).

Hexokinase 2 modulator Comp-1 is a potent, selective small molecule modulator of Hexokinase 2 (HK2) interaction with the mitochondria, selectively dissociates HK2 from VDAC1 in vitro with IC50 of 92 nM.

Hexaminolevulinate hydrochloride is a fluorescent agent, has approved for cystoscopic detection of papillary bladder cancer.

Hexamethylquercetagetin is a polymethoxylated flavone in peels of citrus cultivars.

Hexacosanoic acid is a long-chain fatty acid related to various diseases such as adrenoleukodystrophy (ALD), adrenomyeloneuropathy (AMN) and atherosclerosis.

Hetrombopag is a potent, selective, orally-active Thrombopoietin (TPO) receptor agonist.

HET0016 (HET-0016) is a potent, selective inhibitor of CYP4A, potently inhibits the formation of 20-HETE with IC50 of 8.9 nM in human renal microsomes.

Hesperidin

Herboxidiene (GEX1A, TAN-1609) is a polyketide molecule first isolated from the fermentation broth of Streptomyces chromofuscus, shows in vitro antitumor activity by targeting the SF3B protein in the splicesosome.

HER2-IN-3 is a type I HER2 inhibitor that has a similar profile to HER2-IN-2.

HER2-IN-2 is a potent, selective HER2 inhibitor, only shows potent inhibition for EGFR and Abl in a panel of kinases.

Heptamethine cyanine dye-1 is a near-infrared cyanine dye for fluorescence imaging in biological systems.

Hemin, a physiological erythroid maturation stimulator, is able to induce the expression of critical autophagic genes (Map1a1b (LC3), Beclin-1 gen, Atg5) in an erythroleukemia cell type.

Hemicholinium-3 (HC-3) is a competitive, small molecule inhibitor of choline kinase (ChoK) with ex vivo IC50 of 500 uM, also bolcks the sodium and chloride-dependent transport system and affects choline acetyltransferase.

Helenalin (NSC 85236) is a sesquiterpene lactone that covalently targets Cys38 on p65 transcription factor in the canonical NF-κB signaling pathway.

Hedgehog-IN-7d is a potent, cell-permeable Hedgehog (Hh) pathway inhibitor that inhibits Gli transcription activity with an IC50 value of 70 nM..

HEC-73543 is a novel potent, selective, orally bioavailable FLT3 inhibitor for the treatment of refractory acute myeloid leukemia (AML).

HEC72702 is a novel potent, orally active inhibitor of HBV capsid assembly, inhibits HBV-DNA levels in HepG.2.2.15 cells with IC50 of 39 nM.

HDAC6-AR-IN-10 is a potent dual HDAC6/AR inhibitor with IC50 of 35.6 nM/<30 nM, shows weak inhibition on HDAC1/2/3 (IC50>1 uM).

HDAC6 degrader 9c (dHDAC6 9c) is a bifunctional molecule (dHDAC6) that could selectively degrade HDAC6, by conjugating non-selective HDAC inhibitor to a thalidomide-type E3 ligase ligand.